Search
Dec 11, 2023
Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23
Brian Goff highlights data from the phase 2 portion of the RISE UP pivotal study of Mitapivat for SCD that was presented at #ASH23 today.
Dec 10, 2023
Incyte CEO Hervé Hoppenot on axatilimab for GvHD, BET inhibition, oral PD-1s and more from #ASH23
Hervé Hoppenot discusses Incyte's #ASH23 presentations, the company's pipeline, success in dermatology, and how he thinks about Jakafi.
Dec 9, 2023
Mizuho Senior Analyst Mara Goldstein previews the #ASH23 Annual Meeting
Mara Goldstein previews key #ASH23 data from Incyte, Syndax, Autolus, Corvus, IN8bio, and more.
Nov 16, 2023
BMO's Evan Seigerman joins Analyst Thursdays from London
Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.